

Applicants in case T-347/18 R: Laboratoire Pareva (Saint-Martin-de-Crau, France) and Biotech3D Ltd & Co. KG (Gampern, Austria) (represented by: K. Van Maldegem and S. Englebert, lawyers)

Defendant: European Commission (represented by: R. Lindenthal and K. Mifsud-Bonnici, acting as Agents)

Re:

Application pursuant to Articles 278 and 279 TFEU seeking suspension of operation of Commission Implementing Decision (EU) 2018/619 of 20 April 2018 not approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 1, 5 and 6 (OJ 2018 L 102, p. 21) and Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018 L 102, p. 1), and the adoption of any other appropriate interim measures.

Operative part of the order

1. *Cases T-337/18 R and T-347/18 R are joined for the purpose of the present order.*
2. *The applications for interim measures are dismissed.*
3. *The costs are reserved.*

Order of the President of the General Court of 7 September 2018 — Robert v Conseil national de l'ordre des pharmaciens

(Case T-362/18 R)

(Interim measures — Dismissal of the main action — No need to adjudicate)

(2018/C 399/49)

Language of the case: French

Parties

Applicant: Alain Robert (Le Mans, France) (represented by: J.-M. Viala, lawyer)

Defendant: Conseil national de l'ordre des pharmaciens

Re:

Application based on Articles 278 and 279 TFEU, seeking suspension of the operation of the decision of the French Conseil national de l'ordre des pharmaciens of 3 October 2017, upheld by the French Conseil d'État by judgment of 7 February 2018, prohibiting the applicant from practicing as a pharmacist for one year.

Operative part of the order

1. *There is no need to adjudicate on the application for interim measures.*
 2. *Mr. Alain Robert shall bear his own costs.*
-